Dipal Doshi is Chief Executive Officer of Entrada Therapeutics, Inc. (TRDA). The company reported total compensation of $3,837,737 for fiscal year 2025.
| Salary | $635,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,387,428 |
| Option awards | $1,452,059 |
| Non-equity incentive plan | $349,250 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,000 |
| Total | $3,837,737 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Entrada Therapeutics, Inc. filed April 24, 2026, accession 0001689375-26-000021.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $635,000 | $0 | $1,387,428 | $1,452,059 | $349,250 | $0 | $14,000 | $3,837,737 |
| FY2024 | Chief Executive Officer | $610,000 | $0 | $1,437,531 | $1,494,662 | $335,510 | $0 | $13,800 | $3,891,503 |
Totals as disclosed in each year's own compensation disclosure for Entrada Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Dipal Doshi this page | Chief Executive Officer | $3,837,737 |
| Natarajan Sethuraman | President of Research and Development | $2,254,315 |
| Nathan Dowden | President and Chief Operating Officer | $2,223,497 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Entrada Therapeutics, Inc. compensation brief.
Dipal Doshi's compensation sits inside Entrada Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.